Pfizer Stock Buy or Sell? PFE Stocks Forecast

Market Capitalization: 157 958 324 000 $
EBITDA: 11 381 665 000 $
Price to Earnings: 75.61
Quarterly Earnings Growth YOY: -0.764
Quarterly Revenue Growth YOY: -0.413
Trailing PE: 75.61
Forward PE: 12.44
Shares Outstanding: 5646410000






Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Pfizer Stock Buy or Sell? PFE Stocks Analytic Forecasts

Updated on February 27, 2024 (10:19)

Pfizer Inc. (PFE prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the PFE stock market. Experts share their opinions on what to expect from the Pfizer Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Pfizer stocks.

Pfizer Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy PFE Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Oakoff Investments and is titled

“Pfizer Stock: It’s Time To Buy The Dip”

is published on February 12 (2024) and has 4 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • Pfizer’s depressed valuation and strong product pipeline make it the ultimate buying opportunity for income investors in the healthcare sector.
  • Despite a decline in sales of COVID-19 drugs, Pfizer’s operating sales grew by 7% in 2023, driven by new product launches and continued growth.
  • Pfizer’s projected EPS growth and anticipated rise in EBITDA margins suggest a positive trajectory for the company’s stock, in my view.
  • I calculate a growth potential of 20.8% by the end of 2024 and 50.2% by the end of 2025, based on conservative estimates.
  • So I believe investors should consider adding PFE into their long-term portfolio today at the current dividend yield of 6.19% (FY2024 estimate).

The author starts his analytic review with the following:

My Thesis In my opinion, Pfizer Inc. (NYSE:PFE) stock is the ultimate buying opportunity for income investors seeking exposure to the healthcare sector. This is due to the depressed valuation of the company, which comes from negative market sentiment surrounding PFE. With Pfizer’s product pipeline getting stronger and older drugs continuing to generate good FCF, I believe investors should consider buying PFE for their long-term portfolio today at the current dividend yield of 6.19% (FY2024 estimate).

The opinion of the author can be considered quite authoritative.
The number of 3772 followers confirms this.
Oakoff Investments is the contributor of experts community
since 2021 and has 159 works published.


One more noteworthy article is written by Biotech Play Only under the title

“Pfizer Is A Great Investment Over The Next Decade; Buy”

on February 9 (2024) and has 0 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add PFE stocks to your investment portfolio or not, and helps to work out your own Pfizer stock selling strategies:

  • Pfizer is a multinational “big pharma” with deep scientific and commercialization expertise.
  • While the COVID-related product tailwind has become a headwind of late, it still does not justify this low a valuation given the company’s strong pipeline.
  • The COVID money basically gave Pfizer a “free” Seagen, who is the leader in ADC (antibody-drug conjugate) – the drug modality that every big pharma is trying to get in on.
  • While some key drugs from Pfizer are facing a patent cliff, its diverse pipeline will compensate and then some.

Biotech Play Only starts analysis with such words:

0Pfizer Overview Pfizer Inc. (NYSE:PFE) just celebrated its 175th birthday, and is one of the largest so-called “big pharma” in the world. The company became a household name in recent years due to its COVID vaccine (co-developed with BioNtech (BNTX)) and its COVID drug and how both played a key role in fighting the pandemic. In return Pfizer raked in ~$57 Billion USD in revenue as a result of its two COVID products in 2021 and 2022 alone. Yet since its height of $56.33 per share in the late 2021, it is now trading at a decade low of $26.93 per share. So what went wrong?

The author declares an interesting position, and the number of his followers is 394 and it grows, but not that weighty compared to other authors.
Biotech Play Only has 9 works published.
The contributor of experts community since 2021. Has published at least 9 articles.


Another analysis presented by The Asian Investor came out on February 7 (2024). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for PFE stocks. It sounds like

“Pfizer: The 6.3% Yield Is A Appealing”

Article has got 4 likes at the moment and forecasting Bullish trend of the market.

Summarizing the information presented in the review concerning the Pfizer Inc., the expert says the following:

  • Pfizer reported better than expected Q4 earnings, with solid organic top line growth in FY 2023, despite a drop in COVID-19 product revenues.
  • The drop-off in COVID-19 product sales has caused negative sentiment overhang for Pfizer’s shares and the yield to soar above 6%.
  • Pfizer has a strong financial outlook for FY 2024 and has potential catalysts for growth, including the integration of Seagen and cost savings initiatives.
  • With a P/E ratio of less than 10X, income investors can add a top income play with restructuring upside to their portfolios.

And here, what comes first:

Pfizer (NYSE:PFE) submitted a better than expected earnings card for the fourth fiscal quarter last week. Despite a drop-off in COVID-19 related product revenues, Pfizer has been able to deliver solid organic top line growth in the fourth quarter as well as FY 2023. The pharmaceutical giant also confirmed its financial outlook and guided for Y/Y revenue upside in FY 2024. In my opinion, the drop-off in Corminaty and Paxlovid sales has created overly negative sentiment overhang for Pfizer’s shares which has caused the firm’s dividend yield to soar above 6% lately. Pfizer will likely continue to grow its dividend and is targeting $4.0B in cost-savings by the end of the year. With a P/E ratio of less than 10X, the more than 6% yield is a steal!

This author is very popular among the auditory. He has 22542 followers.

The Asian Investor is the contributor of experts community since 2021 and has at least 1012 analytic reviews published.


The Share Price of Pfizer Inc. (PFE) for now

What analysts predict: $32.14
52-week high/low: $40.79 / $25.38

50/200 Day Moving Average: $28.05 / $33.11

The average stock price over the previous 50/200 days. For Pfizer stocks, the 50-day moving average is the resistance level for now. For PFE stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for PFE stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.